← Back to headlines
FDA Review Meeting Scheduled for Compass Pathways' Depression Drug COMP360
An upcoming FDA review meeting will determine the future of Compass Pathways' depression drug candidate COMP360, as the company awaits regulatory feedback on its potential treatment.
25 Mar, 18:10 — 25 Mar, 18:10
Sources
Showing 1 of 1 sources
Related Stories
Iloilo Reinstates Health Protocols Amid Extreme Heat
just now
Four arrested for selling P102 million in fake anti-cancer medicines in Makati
just now
Vigilance Urged After Death of Two Children in Abandoned Car
just now
Long Waiting Lists for Pediatric Eye Doctors in Latvia Lead to Unborn Child Registrations
just now